|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NWD1 |
Gene summary for NWD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NWD1 | Gene ID | 284434 |
| Gene name | NACHT and WD repeat domain containing 1 | |
| Gene Alias | NWD1 | |
| Cytomap | 19p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q149M9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 284434 | NWD1 | HCC1 | Human | Liver | HCC | 7.03e-21 | 2.11e+00 | 0.5336 |
| 284434 | NWD1 | HCC2 | Human | Liver | HCC | 2.75e-38 | 2.24e+00 | 0.5341 |
| 284434 | NWD1 | HCC5 | Human | Liver | HCC | 4.48e-36 | 2.11e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NWD1 | SNV | Missense_Mutation | rs141165642 | c.3964G>A | p.Val1322Ile | p.V1322I | Q149M9 | protein_coding | tolerated(0.22) | benign(0.043) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| NWD1 | SNV | Missense_Mutation | rs371438099 | c.2582N>A | p.Arg861Gln | p.R861Q | Q149M9 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NWD1 | SNV | Missense_Mutation | rs372464599 | c.610N>A | p.Ala204Thr | p.A204T | Q149M9 | protein_coding | tolerated(0.32) | possibly_damaging(0.454) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| NWD1 | SNV | Missense_Mutation | novel | c.1085N>G | p.Leu362Arg | p.L362R | Q149M9 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD |
| NWD1 | SNV | Missense_Mutation | rs369799191 | c.2363N>A | p.Arg788His | p.R788H | Q149M9 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD |
| NWD1 | SNV | Missense_Mutation | novel | c.2327N>T | p.Ala776Val | p.A776V | Q149M9 | protein_coding | tolerated(0.23) | benign(0.027) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NWD1 | SNV | Missense_Mutation | novel | c.2126A>G | p.Asp709Gly | p.D709G | Q149M9 | protein_coding | deleterious(0) | possibly_damaging(0.71) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NWD1 | SNV | Missense_Mutation | rs148020552 | c.3800G>A | p.Arg1267His | p.R1267H | Q149M9 | protein_coding | tolerated(0.21) | benign(0) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NWD1 | SNV | Missense_Mutation | rs148848880 | c.943C>T | p.Arg315Cys | p.R315C | Q149M9 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NWD1 | SNV | Missense_Mutation | c.1405N>C | p.Cys469Arg | p.C469R | Q149M9 | protein_coding | tolerated(0.09) | probably_damaging(0.961) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |